GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$80.34
−0.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 165.3M | 147.2M | 125.6M | 93.1M | 55.5M |
| Cost of Revenue | 183.2M | 209.7M | 203.6M | 188.7M | 172.0M |
| Gross Profit | (17.9M) | (62.6M) | (78.0M) | (95.6M) | (116.4M) |
| Operating Expenses | |||||
| R&D Expense | 191.0M | 195.8M | 322.4M | 338.7M | 329.6M |
| SG&A Expense | 291.1M | 275.8M | 367.8M | 362.6M | 296.4M |
| General & Admin Expense | 169.6M | 159.1M | 213.9M | 200.3M | 174.1M |
| Selling & Marketing Expense | 121.5M | 116.7M | 154.0M | 162.3M | 122.3M |
| Other Expenses | 59.3M | — | 1.4B | 718.5M | 4.7B |
| Total Operating Expenses | 541.4M | 471.6M | 2.1B | 1.4B | 5.3B |
| Cost and Expenses | 724.5M | 681.3M | 2.3B | 1.6B | 5.5B |
| Operating Income (EBIT) | (559.3M) | (534.2M) | (2.2B) | (1.5B) | (5.4B) |
| Non-Operating | |||||
| Interest Income | 29.3M | 28.7M | 26.7M | 8.0M | 1.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 29.3M | 28.7M | 26.7M | 8.0M | 1.7M |
| Other Non-Op Income/Expense | 29.8M | (341.0K) | 26.8M | 7.7M | 1.5M |
| Non-Operating Income (excl Interest) | (29.8M) | 341.0K | (1.4B) | (718.5M) | (4.7B) |
| EBT (Pre-Tax Income) | (529.5M) | (534.5M) | (2.2B) | (1.5B) | (5.4B) |
| Income Tax Expense | (137.9M) | (126.2M) | (135.4M) | (42.0M) | (42.3M) |
| Bottom Line | |||||
| Net Income | (391.6M) | (408.4M) | (2.0B) | (1.5B) | (5.4B) |
| Earnings from Cont. Ops | (391.6M) | (408.4M) | (2.0B) | (1.5B) | (5.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (391.6M) | (408.4M) | (2.0B) | (1.5B) | (5.4B) |
| Per Share | |||||
| Basic EPS | ($9.75) | ($11.11) | ($63.54) | ($47.20) | ($173.87) |
| Diluted EPS | ($9.75) | ($11.11) | ($63.54) | ($47.20) | ($173.87) |
| Revenue Per Share | $3.83 | $4.00 | $3.94 | $3.00 | $1.79 |
| Shares | |||||
| Basic Shares Outstanding | 43.1M | 36.8M | 31.9M | 31.1M | 31.1M |
| Diluted Shares Outstanding | 43.1M | 36.8M | 31.9M | 31.1M | 31.1M |
| Profitability Metrics | |||||
| EBITDA | (412.8M) | (378.2M) | (610.2M) | (638.2M) | (587.7M) |
| D&A | 116.7M | 156.3M | 158.1M | 158.7M | 154.8M |
| EBIT | (529.5M) | (534.5M) | (768.2M) | (796.9M) | (742.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026